RA Capital Management L.P. Buys Shares of 4,451,041 Kura Oncology, Inc. (NASDAQ:KURA)

RA Capital Management L.P. bought a new stake in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 4,451,041 shares of the company's stock, valued at approximately $38,769,000. RA Capital Management L.P. owned 5.72% of Kura Oncology at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Marshall Wace LLP bought a new position in Kura Oncology in the fourth quarter worth approximately $8,265,000. Vanguard Group Inc. grew its position in shares of Kura Oncology by 14.6% during the 4th quarter. Vanguard Group Inc. now owns 4,818,898 shares of the company's stock worth $41,973,000 after buying an additional 615,211 shares in the last quarter. Trexquant Investment LP increased its stake in shares of Kura Oncology by 867.8% during the fourth quarter. Trexquant Investment LP now owns 566,945 shares of the company's stock valued at $4,938,000 after buying an additional 508,362 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Kura Oncology by 463.4% in the fourth quarter. Renaissance Technologies LLC now owns 597,810 shares of the company's stock valued at $5,207,000 after acquiring an additional 491,700 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Kura Oncology by 35.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,425,960 shares of the company's stock worth $12,419,000 after acquiring an additional 372,196 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of Kura Oncology in a report on Monday, April 28th. Wedbush reaffirmed an "outperform" rating and set a $36.00 price target on shares of Kura Oncology in a research report on Tuesday, April 8th. Scotiabank lowered their price target on Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a report on Wednesday, January 8th. StockNews.com lowered Kura Oncology from a "buy" rating to a "hold" rating in a research note on Friday. Finally, BTIG Research lowered shares of Kura Oncology from a "buy" rating to a "neutral" rating in a research report on Thursday, February 6th. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $23.89.

Kura Oncology Stock Down 13.1 %

Shares of Kura Oncology stock traded down $0.88 on Tuesday, reaching $5.84. 1,171,519 shares of the company were exchanged, compared to its average volume of 1,159,103. The stock's 50 day moving average price is $6.70 and its 200-day moving average price is $9.44. The company has a market cap of $471.74 million, a P/E ratio of -2.47 and a beta of 0.50. Kura Oncology, Inc. has a 1-year low of $5.41 and a 1-year high of $23.48. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The company had revenue of $14.11 million for the quarter, compared to analysts' expectations of $39.08 million. As a group, equities analysts forecast that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.